SRX HEALTH SOLUTIONS INC (SRXH) Stock Fundamental Analysis

NYSEARCA:SRXH • US08771Y4026

0.1252 USD
0 (-3.02%)
At close: Feb 27, 2026
0.124 USD
0 (-0.96%)
After Hours: 2/27/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall SRXH gets a fundamental rating of 3 out of 10. We evaluated SRXH against 38 industry peers in the Consumer Staples Distribution & Retail industry. SRXH has only an average score on both its financial health and profitability. SRXH has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year SRXH has reported negative net income.
  • In the past year SRXH has reported a negative cash flow from operations.
  • In the past 5 years SRXH reported 4 times negative net income.
  • In the past 5 years SRXH reported 4 times negative operating cash flow.
SRXH Yearly Net Income VS EBIT VS OCF VS FCFSRXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • With an excellent Return On Assets value of 19.91%, SRXH belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • SRXH has a better Return On Equity (411.06%) than 100.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 571.65%, SRXH belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA 19.91%
ROE 411.06%
ROIC 571.65%
ROA(3y)-79.59%
ROA(5y)-70.15%
ROE(3y)-316.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRXH Yearly ROA, ROE, ROICSRXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

1.3 Margins

  • The Profit Margin of SRXH (2.77%) is better than 71.05% of its industry peers.
  • The Operating Margin of SRXH (58.30%) is better than 100.00% of its industry peers.
  • SRXH has a Gross Margin (21.54%) which is comparable to the rest of the industry.
  • SRXH's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 58.3%
PM (TTM) 2.77%
GM 21.54%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.59%
GM growth 5Y-0.26%
SRXH Yearly Profit, Operating, Gross MarginsSRXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SRXH is creating value.
  • The number of shares outstanding for SRXH has been increased compared to 1 year ago.
  • Compared to 5 years ago, SRXH has more shares outstanding
  • The debt/assets ratio for SRXH has been reduced compared to a year ago.
SRXH Yearly Shares OutstandingSRXH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M
SRXH Yearly Total Debt VS Total AssetsSRXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • An Altman-Z score of 18.50 indicates that SRXH is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of SRXH (18.50) is better than 100.00% of its industry peers.
  • SRXH has a Debt/Equity ratio of 10.94. This is a high value indicating a heavy dependency on external financing.
  • SRXH has a worse Debt to Equity ratio (10.94) than 92.11% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.94
Debt/FCF N/A
Altman-Z 18.5
ROIC/WACC73.76
WACC7.75%
SRXH Yearly LT Debt VS Equity VS FCFSRXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • SRXH has a Current Ratio of 2.29. This indicates that SRXH is financially healthy and has no problem in meeting its short term obligations.
  • SRXH's Current ratio of 2.29 is amongst the best of the industry. SRXH outperforms 89.47% of its industry peers.
  • A Quick Ratio of 1.71 indicates that SRXH should not have too much problems paying its short term obligations.
  • With an excellent Quick ratio value of 1.71, SRXH belongs to the best of the industry, outperforming 89.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.29
Quick Ratio 1.71
SRXH Yearly Current Assets VS Current LiabilitesSRXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 93.37% over the past year.
  • Looking at the last year, SRXH shows a very strong growth in Revenue. The Revenue has grown by 79.93%.
  • The Revenue has been growing by 17.56% on average over the past years. This is quite good.
EPS 1Y (TTM)93.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.59%
Revenue 1Y (TTM)79.93%
Revenue growth 3Y-8.73%
Revenue growth 5Y17.56%
Sales Q2Q%382.51%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SRXH Yearly Revenue VS EstimatesSRXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
SRXH Yearly EPS VS EstimatesSRXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • SRXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRXH Price Earnings VS Forward Price EarningsSRXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SRXH is valued cheaper than 94.74% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.34
SRXH Per share dataSRXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for SRXH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SRX HEALTH SOLUTIONS INC

NYSEARCA:SRXH (2/27/2026, 8:04:00 PM)

After market: 0.124 0 (-0.96%)

0.1252

0 (-3.02%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)12-05
Earnings (Next)03-25
Inst Owners1.22%
Inst Owner ChangeN/A
Ins Owners62.05%
Ins Owner Change0%
Market Cap8.71M
Revenue(TTM)60.31M
Net Income(TTM)1.67M
Analysts82.86
Price Target10.2 (8046.96%)
Short Float %11.63%
Short Ratio0.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.14
P/FCF N/A
P/OCF N/A
P/B 21.4
P/tB 21.4
EV/EBITDA 0.34
EPS(TTM)-1.33
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.06
FCFYN/A
OCF(TTM)-0.06
OCFYN/A
SpS0.87
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 19.91%
ROE 411.06%
ROCE 723.61%
ROIC 571.65%
ROICexc 782.43%
ROICexgc 782.43%
OM 58.3%
PM (TTM) 2.77%
GM 21.54%
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-70.15%
ROE(3y)-316.39%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.59%
GM growth 5Y-0.26%
F-Score4
Asset Turnover7.18
Health
Industry RankSector Rank
Debt/Equity 10.94
Debt/FCF N/A
Debt/EBITDA 0.13
Cap/Depr 31.54%
Cap/Sales 0.07%
Interest Coverage 143.51
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.29
Quick Ratio 1.71
Altman-Z 18.5
F-Score4
WACC7.75%
ROIC/WACC73.76
Cap/Depr(3y)14.78%
Cap/Depr(5y)14.84%
Cap/Sales(3y)0.18%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.59%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)79.93%
Revenue growth 3Y-8.73%
Revenue growth 5Y17.56%
Sales Q2Q%382.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y513.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5667.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4591.75%
OCF growth 3YN/A
OCF growth 5YN/A

SRX HEALTH SOLUTIONS INC / SRXH FAQ

What is the ChartMill fundamental rating of SRX HEALTH SOLUTIONS INC (SRXH) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SRXH.


Can you provide the valuation status for SRX HEALTH SOLUTIONS INC?

ChartMill assigns a valuation rating of 1 / 10 to SRX HEALTH SOLUTIONS INC (SRXH). This can be considered as Overvalued.


What is the profitability of SRXH stock?

SRX HEALTH SOLUTIONS INC (SRXH) has a profitability rating of 4 / 10.


What is the financial health of SRX HEALTH SOLUTIONS INC (SRXH) stock?

The financial health rating of SRX HEALTH SOLUTIONS INC (SRXH) is 5 / 10.